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Migration and invasion of drug-resistant lung
adenocarcinoma cells are dependent on mitochondrial
activity
Ji Hoon Jeon1,6, Dong Keon Kim1,2,6, Youngmi Shin1,6, Hee Yeon Kim1,3, Bomin Song1, Eun Young Lee1,
Jong Kwang Kim1, Hye Jin You1,3, Heesun Cheong1,3, Dong Hoon Shin1,3, Seong-Tae Kim2, Jae-Ho Cheong4,5,
Soo Youl Kim1 and Hyonchol Jang1,3
A small proportion of cancer cells have stem-cell-like properties, are resistant to standard therapy and are associated with a poor
prognosis. The metabolism of such drug-resistant cells differs from that of nearby non-resistant cells. In this study, the
metabolism of drug-resistant lung adenocarcinoma cells was investigated. The expression of genes associated with oxidative
phosphorylation in the mitochondrial membrane was negatively correlated with the prognosis of lung adenocarcinoma. Because
the mitochondrial membrane potential (MMP) reﬂects the functional status of mitochondria and metastasis is the principal cause
of death due to cancer, the relationship between MMP and metastasis was evaluated. Cells with a higher MMP exhibited greater
migration and invasion than those with a lower MMP. Cells that survived treatment with cisplatin, a standard chemotherapeutic
drug for lung adenocarcinoma, exhibited increased MMP and enhanced migration and invasion compared with parental cells.
Consistent with these ﬁndings, inhibition of mitochondrial activity signiﬁcantly impeded the migration and invasion of cisplatin-
resistant cells. RNA-sequencing analysis indicated that the expression of mitochondrial complex genes was upregulated in
cisplatin-resistant cells. These results suggested that drug-resistant cells have a greater MMP and that inhibition of
mitochondrial activity could be used to prevent metastasis of drug-resistant lung adenocarcinoma cells.
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INTRODUCTION
Lung cancer accounted for 22.8% of all deaths due to cancer
in Korea in 2013.1 Approximately 85–90% of all cases
of lung cancer are characterized as non-small-cell lung
cancer (NSCLC), for which platinum-based chemotherapy
is the standard ﬁrst-line treatment.2 Among NSCLCs,
adenocarcinoma is the most common type in Korea.3 Despite
advances in cancer treatment, treatment fails in many cases,
resulting in disease progression, recurrence and metastasis.4
One of the major reasons for treatment failure is intratumoural
heterogeneity; a small number of cells have stem-cell-like
properties (or stemness), and can survive treatment with
common anticancer drugs.4,5 Cancer cells with stemness are
also the principal population that undergoes metastasis.6–8
Reprogramming of energy metabolism is one of the
hallmarks of cancer9 and a target for anticancer drug
development.10 Much evidence suggests that the metabolism
of tumor cells is heterogeneous.11 In particular, cancer cells
with stemness have a metabolism distinct from that of nearby
non-stemness cells.11 For example, cancer cells generally rely
on glycolysis to support their rapid proliferation; however,
in ovarian,12 breast13 and colon14 cancer, proliferation of
cells with stemness is dependent on mitochondrial energy
production.
To reduce the number of deaths due to cancer, it is
important to eradicate or prevent metastasis by cancer cells
with stemness. Because stemness populations must survive
standard treatments before undergoing metastasis, controlling
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the drug-resistant cancer cell population is vital. This could be
achieved by exploiting the difference in metabolism between
the overall cancer cell population and those resistant to
therapeutics. Therefore, the difference in metabolism between
the overall cancer cell population and the drug-resistant
population was investigated in this study. The results revealed
that the drug-resistant population of NSCLC adenocarcinoma
cells exhibited a higher mitochondrial membrane potential
(MMP) and enhanced migration and invasion compared
with the parental cell population. Moreover, inhibition of
mitochondrial activity hampered the migration and invasion
of the drug-resistant cell population. These ﬁndings suggested
that treatment with mitochondria inhibitors could reduce the
incidence of metastasis of lung adenocarcinoma following
platinum-based therapy.
MATERIALS AND METHODS
Cell culture and chemicals
Human non-small-cell lung cancer (NSCLC) adenocarcinoma cell
lines, A549 and H1650, were purchased from Korean Cell Line Bank
(KCLB, Seoul, Korea) and cultured in RPMI (Hyclone, Logan, UT,
USA) supplemented with 10% fetal bovine serum (Hyclone) and 1%
penicillin–streptomycin at 37 °C in 5% CO2 humidiﬁed incubators.
Rotenone (#R8875), cisplatin (#c2210000), SRB (Sulforhodamine B;
#S1402) were purchased from Sigma-Aldrich (St Louis, MO, USA).
JC-1 (5,5′,6,6′-tetrachloro- 1,1′,3,3′-tetraethyl benzimidazolyl
carbocyanine iodide; M34152) was from Molecular Probe (Eugene,
OR, USA), TMRE (Tetramethylrhodamine ethyl ester; ab113852) was
from Abcam (Cambridge, UK), MitoTrackerGreen FM (#9074)
was from Cell Signaling (Danvers, MA, USA), 7-AAD (7-amino
actinomycin D; #559925) was from BD BioSciences (San Jose, CA,
USA), DAPI (4′,6-diamidino-2-phenylindole, #268298) was from
Calbiochem (La Jolla, CA, USA), and PrestoBlue cell viability reagent
(#A13262) was from Invitrogen (Carlsbad, CA, USA).
Flow cytometry analysis and cell sorting
Flow cytometry analysis was done as reported previously15 at Flow
Cytometry Core (National Cancer Center). MMP and contents were
analyzed by ﬂow cytometry using JC-1, TMRE and MitoTracker as per
the manufacturer’s instructions. Brieﬂy, cells were dissociated to single
cells using trypsin/EDTA and incubated with JC-1 (2 μM) alone or
both TMRE (100 nM) and 7-AAD (2.5 μg ml− 1) or MitoTracker
(400 nM) alone, then analyzed by FACSVerse ﬂow cytometry
(BD Biosciences). For cell sorting, dissociated single cells were stained
with JC-1 and cells with upper and lower 20% of MMP were sorted
using FACSort ﬂow cytometry (BD Biosciences).
Migration and invasion assay
Boyden chamber migration and invasion assay were done as reported
previously.16
Adenosine triphosphate measurement
Cells were seeded in 96-well plates (1× 104 cells per well),
cellular adenosine triphosphate (ATP) level was measured using a
CellTiter-Glo Luminescent Cell Viability Assay kit (#G7572, Promega,
Madison, WI, USA) as per the manufacturer’s instructions as reported
previously.17
Cell proliferation and viability assay
Proliferation rate was determined by SRB colorimetric assay as
reported.18 Brieﬂy, cells were ﬁxed with 50% trichloroacetic acid
and dried, then stained with 0.4% SRB solution. The protein-bound
dye was dissolved by 10 mM Tris base solution and the optical density
was determined at 515 nm using a microplate reader (Molecular
Devices, Sunnyvale, CA, USA). Cell viability was quantiﬁed by
PrestoBlue cell viability reagent (Invitrogen) as per the manufacturer’s
instructions.
RNA sequencing
Total RNA from A549 and A549R cells were extracted with Trizol
(Invitrogen) as per the manufacturer’s instruction. Preparation of
RNA library and sequencing were performed by Macrogen (Seoul,
Korea). RNA library was prepared using TruSeq RNA kit (Illumina,
San Diego, CA, USA) and sequencing was done using HiSeq 2000
sequencing system (Illumina).
Real-time imaging of mitochondrial membrane potential
Both green and red ﬂuorescent image and bright ﬁeld image of A549
cells treated with JC-1 (2 μM) were acquired in an IncuCyte ZOOM
live-cell imaging system (Essen BioScience, Ann Arbor, MI, USA) with
a × 10 objective for 24 h in every 2 h interval.
Image-based quantiﬁcation of cell number
Cells were incubated with DAPI (2 μg ml− 1) for 20 min at room
temperature and analyzed using the Cytation-3 cell imaging
multi-mode microplate reader with a × 4 objective (Bio-Tek,
Winooski, VT, USA).
Mitochondrial complex 1 enzyme activity
Complex 1 activity was quantiﬁed by a complex 1 enzyme activity
dipstick assay kit (ab109720, Abcam) as per the manufacturer’s
instructions. Brieﬂy, lysates from 1×105–4× 106 of A549 and
A549R cells were allowed to wick up into the dipstick, which
immunocaptured complex 1. The dipstick was immersed in complex 1
activity buffer solution containing NADH as a substrate and
nitrotetrazolium blue as the electron acceptor. Reduced nitrotetrazo-
lium blue formed a blue–purple precipitate at the complex 1 antibody
line on the dipstick, whose signal intensity was corresponded to the
level of complex 1 activity.
Statistics
Statistical analysis was done as reported.19 Brieﬂy, data were presented
as means± s.d., and P-values were calculated using the Student’s t-test
calculator. All data were representative of at least three separate
experiments.
RESULTS
Expression of mitochondrial membrane genes is negatively
correlated with the prognosis of lung adenocarcinoma
The relationship between the expression of energy metabolism-
related genes and prognosis was evaluated using a Kaplan–
Meier survival plot generated by a meta-analysis of published
lung cancer microarray data sets20 (Supplementary Table 1).
In total, 866 lung adenocarcinoma patients were categorized
according to the median expression level of speciﬁc genes, and
the difference in overall survival was investigated. Genes with a
P-value o0.05 were considered to be signiﬁcantly associated
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with prognosis. If one gene has multiple probes (Affymetrix
identiﬁcation; Afﬁd) showing different prognosis, that gene was
regarded as ‘no difference or unclear’. The percentage of genes
in each metabolic pathway subset associated with prognosis
was evaluated and is presented as a circular diagram. The
results suggested that the majority of metabolism-related genes
was correlated with prognosis (Figure 1a and Supplementary
Table 1). Consistent with previous reports that many
glycolytic genes are upregulated in cancer cells and are
candidate targets for the development of anticancer
drugs,21,22 ~ 50% of glycolysis-related genes were negatively
correlated with prognosis. Interestingly, the majority of genes
whose products mediate oxidative phosphorylation (OxPhos)
in the mitochondrial membrane were negatively correlated
with prognosis (Figures 1a and b). These genes, the products of
which comprise mitochondrial OxPhos complexes I, III and
IV, create the MMP by generating a proton gradient across the
inner mitochondrial membrane (Figure 1c). Thus, it was
hypothesized that the MMP is associated with the prognosis
of lung cancer.
High-MMP cells exhibit increased migration and invasion
Because the major cause of death due to cancer is metastasis,23
the prognosis is closely correlated with the rate of metastasis.
Thus, the relationship between MMP and metastasis was
investigated in this study. MMP, which reﬂects the functional
status of mitochondria, differs among individual cells under
normal growth conditions.24 First, the heterogeneity of the
MMP in lung adenocarcinoma cells was assessed. JC-1 stains
low-MMP cells as green and high-MMP cells as red due to
MMP-dependent accumulation of JC-1 dye in mitochondria,
which results in a shift in ﬂuorescence emission from green to
red. Real-time ﬂuorescence imaging showed that JC-1-stained
lung adenocarcinoma cells had various MMP levels,
which were dynamic over a 24-h period (Figure 2a and
Supplementary Movie 1). The majority of high-MMP cells
retained a high MMP, whereas a proportion of low-MMP cells
became high-MMP cells within 24 h. After 24 h, 80% of the
total number of high-MMP cells originated from high-MMP
cells, and 20% originated from low-MMP cells (Figure 2b).
This result suggested that lung adenocarcinoma cells could be
grouped into high- and low-MMP cells and maintain their
high- or low-MMP status for at least 24 h.
Cells were sorted according to their MMP level; the upper
and lower 20% of cells were termed high- and low-MMP cells,
respectively (Figure 2c). The difference in MMP was not
signiﬁcantly associated with the proliferation rate (Figure 2d),
suggesting that low-MMP cells were not dead or damaged. In
Figure 1 The expression of energy metabolism-related genes is negatively correlated with the prognosis of lung adenocarcinoma.
(a) Correlations between the expression of energy metabolism-related genes and prognosis were analyzed using an open database20 with
the data of 866 lung adenocarcinoma patients. The percentage of genes associated with a particular prognosis in each metabolic pathway
subset is shown. Blue, positive prognosis; red, negative prognosis; gray, no difference in prognosis or unclear. (b) Mitochondrial complex 1
genes and their associations with overall survival. A list of all genes in speciﬁc metabolic pathways and their correlations with prognosis is
shown in Supplementary Table 1. (c) Schematic diagram of the associations of mitochondrial oxidative phosphorylation (OxPhos) complex
genes with MMP.
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Transwell migration experiments, the migration of low-MMP
cells was found to be inferior to that of high-MMP cells
(Figure 2e). Moreover, low-MMP cells exhibited a lower
invasion capacity than high-MMP cells (Figure 2f). These
results suggested that high-MMP cancer cells were more likely
to lead to metastasis than low-MMP cells.
Cisplatin-resistant cells have a high MMP and exhibit
increased migration and invasion
The majority of cancer cells are killed by chemotherapy;
however, a small population of drug-resistant cells survive,
and these can lead to metastasis. The MMP and metastasis
potential of these drug-resistant cells were thus investigated.
The half-maximal inhibitory concentration (IC50) of cisplatin,
a standard chemotherapeutic, for A549 cells was 1.0 μM
(Figure 3a). A549 cells were treated with 10 μM cisplatin for
3 days, followed by culture in the absence of cisplatin for 2 days
(Figure 3b). The majority of A549 cells eventually underwent
apoptosis; however, some cells survived after 5 days (Figure 3c
and Supplementary Movie 2). Indeed, almost all cells viable on
day 5 survived for further 8 days (Figure 3d). The proliferation
rate of the surviving cells on day 5 was reduced greatly
compared with parental cells (Figure 3e). Moreover, the
surviving cells on day 5 were resistant to a further three cycles
of 3-day cisplatin treatment (Figure 3f). These cells were thus
considered cisplatin-resistant cells and named A549R cells.
Drug-resistant H1650 cells were obtained by treatment with
5 μM cisplatin and were named H1650R cells (data not shown).
The MMP of parental (A549 and H1650) and cisplatin-
resistant (A549R and H1650R) cells was measured by TMRE
Figure 2 High-MMP cells exhibit increased migration and invasion. (a) The time course of changes in the MMP of A549 cells was
investigated by JC-1 (5,5′,6,6′-tetrachloro-1,1′,3′,3′-tetraethyl benzimidazolyl carbocyanine iodide) staining and real-time ﬂuorescence
microscopy using IncuCyte ZOOM (Essen BioScience). Cells were imaged at 2-h intervals for 24 h; a representative image is shown.
Images of the entire time course are shown in Supplementary Movie 1. Red, high-MMP cells; green; low-MMP cells; black arrow,
MMP-unchanged cells; white arrow, MMP-changed cells. (b) The change in MMP over 24 h was quantiﬁed. (c) A549 and H1650 cells
stained with JC-1 were sorted according to their MMP level by ﬂow cytometry using a FACSort ﬂow cytometer (BD Biosciences). Cells in
the highest and lowest 20% MMP categories were labelled high- and low-MMP cells, respectively. (d) The proliferation rates of high- and
low-MMP cells were determined by sulforhodamine B (SRB) assay. (e, f) High-MMP cells exhibited increased migration and invasion.
Migration and invasion of high- and low-MMP cells were assessed by Transwell migration and invasion assays. Data are representative of at
least three independent experiments. *Po0.05, **Po0.01, ***Po0.001 relative to high-MMP cells.
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Figure 3 Cisplatin-resistant cells had a high MMP and increased migration and invasion. (a) A549 cells were treated with the indicated
concentrations of cisplatin for 3 days. The half-maximal inhibitory concentration (IC50) of cisplatin for A549 cells was determined by SRB
assay. (b) Schematic diagram of cisplatin treatment. (c) A small population of lung adenocarcinoma cells was resistant to cisplatin
treatment. A549 cells treated with cisplatin (10 μM) as indicated in b were imaged at 2-h intervals for 5 days using IncuCyte ZOOM (Essen
Bioscience); a representative image is shown. Full time-course images are shown in Supplementary Movie 2. (d) After withdrawal of
cisplatin, A549R cells remained viable but did not proliferate signiﬁcantly. The majority existed as single cells and were viable at 10 days
after cisplatin withdrawal. (e) The proliferation rates of A549 and A549R cells were determined by cell counting using Cytation 3
(Bioteck). (f) A549R cells survived a further three cycles of cisplatin treatment. (g) Cisplatin-resistant cells had a higher MMP than
parental cells. The MMPs of parental (A549 and H1650) and cisplatin-resistant (A549R and H1650R) cells were investigated by
tetramethylrhodamine, ethyl ester (TMRE) staining followed by ﬂow cytometry (FACSVerse; BD Biosciences). 7-Amino actinomycin D
(7-AAD) staining was used to evaluate cell viability. (h) Cisplatin-resistant cells had a greater number of mitochondria than parental cells.
Parental and cisplatin-resistant cells were stained with Mitotracker and analyzed by ﬂow cytometry. (i) Cisplatin-resistant cells had a higher
cellular ATP level than parental cells, as determined using an ATP assay kit. (j, k) Cisplatin-resistant cells exhibited increased migration
and invasion, as determined by Transwell migration and invasion assays. Data are means of at least three independent experiments.
*Po0.05, **Po0.01, ***Po0.001 relative to parental cells.
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staining followed by ﬂow cytometry. Cell viability was assayed
using 7-AAD, a membrane-impermeable ﬂuorescent dye that is
generally excluded from viable cells. The MMP of cisplatin-
resistant A549R and H1650R cells was signiﬁcantly higher
than that of parental A549 and H1650 cells (Figure 3g).
Flow cytometry analysis using MitoTracker Green FM, which
accumulates in active mitochondria, also showed that the
mitochondria of cisplatin-resistant cells were more active than
those of parental cells (Figure 3h). Moreover, cisplatin-resistant
cells had a higher cellular ATP level than parental cells
(Figure 3i). As drug-resistant cells had higher MMP and ATP
levels, their migration and invasion were evaluated. A Transwell
migration and invasion assay showed that drug-resistant cells
exhibited increased migration and invasion compared with
parental cells (Figures 3j and k).
Inhibition of mitochondrial activity reduced migration and
invasion of cisplatin-resistant cells
As high-MMP cells exhibited greater migration and invasion
than low-MMP cells and cisplatin-resistant cells showed a
higher MMP and enhanced migration and invasion (Figures 2
and 3), the question of whether mitochondrial activity was
required for the migration and invasion of drug-resistant cells
was investigated. First, the effect of inhibition of mitochondrial
activity on the migration of lung adenocarcinoma cells was
determined. Cisplatin-resistant cells exhibited increased mito-
chondrial complex 1 activity compared with parental cells
(Figure 4a and Supplementary Figure S1). Nanomolar con-
centrations of Rotenone, an inhibitor of mitochondrial OxPhos
complex 1,25 signiﬁcantly reduced the migration of A549 and
H1650 cells in a dose-dependent manner (Figure 4b). Because
Rotenone at nanomolar concentrations did not cause the
deaths of A549 and H1650 cells (Figure 4c) and other lung
adenocarcinoma cells,26 their decreased migration was not due
to a reduction in viability.
The dependence of the migration and invasion of drug-
resistant cells on mitochondrial activity was next evaluated.
Treatment with 10 nM Rotenone signiﬁcantly reduced the
migration and invasion of cisplatin-resistant cells (Figures 4d
and e). To exclude the possibility that the decreased invasion
Figure 4 Inhibition of mitochondrial activity reduced the migration and invasion of cisplatin-resistant cells. (a) Mitochondrial complex 1
activities of A549 and A549R cells were determined by a complex 1 enzyme activity dipstick assay kit. (b) Rotenone, a mitochondria
complex 1 inhibitor, inhibited the migration of lung adenocarcinoma cells in a dose-dependent manner. During migration assays of A549
and H1650 cells, Rotenone was added at the indicated doses. (c) Rotenone at low doses did not cause cell death. A549 and H1650 cells
were treated with the indicated doses of Rotenone for 24 h, and cell viability was assessed using the PrestoBlue cell-viability reagent
(Invitrogen). (d, e) A low dose of Rotenone inhibited the migration and invasion of cisplatin-resistant cells. Cisplatin-resistant cells (A549R
and H1650R cells) were treated with or without Rotenone (10 nM) during migration and invasion assays. (f) Rotenone did not affect the
viability of cisplatin-resistant cells. A549R cells were treated with or without Rotenone (10 nM) for 3 days, and surviving cells were imaged
and enumerated using Cytation 3 (Bioteck). Data are representative of at least three independent experiments. *Po0.05, **Po0.01,
***Po0.001 relative to non-Rotenone-treated cells.
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was caused by a reduction in cell viability, the effect of 10 nM
Rotenone treatment on the viability of drug-resistant cells was
assessed. Because a small number of cisplatin-resistant cells was
used, enumeration using conventional colourimetric methods
was problematic. Thus, cells were enumerated using a Cytation
3 cell-imaging microplate reader. Viable cells were stained with
4′,6-diamidino-2-phenylindole (DAPI), a ﬂuorescent marker of
the nucleus, and imaged (Supplementary Figure S2). Treatment
with Rotenone (10 nM) had no effect on the number of viable
cells (Figure 4f). These results suggested that mild inhibition of
mitochondrial activity reduces the migration and invasion of
cisplatin-resistant cells without affecting their viability.
Global changes in the expression of metabolism-related
genes in cisplatin-resistant cells
To evaluate the metabolism of cisplatin-resistant cells, the
mRNA levels of relevant genes in A549 and A549R cells were
compared using RNA-sequencing. In total, 1,193 genes were
upregulated and 976 genes were downregulated more than
twofold in A549R cells compared with parental A549 cells
(Figure 5a). Drug efﬂux systems were activated in A549R cells,
as indicated by upregulation of ABC transporters (Figure 5b).
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis showed that differentially expressed genes were
enriched in the metabolic process category (Figure 5c and
Supplementary Table 2). The majority of upregulated genes
were in the drug-detoxiﬁcation category, and the majority of
downregulated genes were related to DNA synthesis-related
metabolism (Figure 5d). Among genes related to the mito-
chondrial OxPhos complex, all those whose expression was
changed signiﬁcantly were upregulated, suggesting enhance-
ment of mitochondrial activity in cisplatin-resistant cells
(Figure 5e and Supplementary Figure S3).
DISCUSSION
Intratumoural heterogeneity and cancer stemness are the
principal causes of failure of cancer therapy. In many cases, a
small population of drug-resistant cells survives after ﬁrst-line
Figure 5 Global changes in the expression of metabolism genes in cisplatin-resistant cells. (a) Differentially expressed genes (DEGs)
between parental and cisplatin-resistant cells (A549 and A549R cells) were analyzed by RNA sequencing. Genes whose expression
changed more than twofold are shown. (b) Drug-efﬂux systems were activated in A549R cells. Various ABC transporters were upregulated
in A549R cells. (c) Metabolic process was the dominant pathway altered in A549R cells according to Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis. The top 10 pathways are presented; full analysis results are shown in Supplementary Table 2. (d) Drug
detoxiﬁcation and DNA synthesis-related metabolism were up- and downregulated, respectively, in A549R cells. Up- and downregulated
DEGs in the metabolic process category were subjected to KEGG pathway analysis. Pathway maps with a P-value o1×10−4 are shown.
(e) Genes related to OxPhos-complexes I and V were upregulated in A549R cells. All DEGs related to the OxPhos complexes whose
expression changed more than twofold are shown.
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standard therapy, which can lead to metastasis and recurrence.
Identiﬁcation of the difference in metabolism between
drug-resistant and parental cells might suggest a method of
eradicating the former. In this study, the MMP of cisplatin-
resistant NSCLC cells was increased (Figure 3). In addition,
KEGG pathway analysis of RNA-sequencing data showed
that the expression of mitochondrial membrane genes was
upregulated in cisplatin-resistant compared with parental cells
(Figure 5). These results suggested that drug-resistant cells are
more reliant on mitochondria for energy production compared
with parental cells.
The lung cancer cells showed diverse mitochondrial activity,
as determined by JC-1 and TMRE staining (Figure 2). The time
course of changes in the MMP in lung cancer cells has not been
reported previously. In this study, the time required for the
MMP of individual cells to change was determined in a semi-
quantitative manner (Figures 2a and b). The data suggested
that the MMP of lung adenocarcinoma cells did not change
greatly during performance of Transwell migration/invasion
assays, which were 12–16 h in duration. The Transwell
migration/invasion assay results showed that high-MMP cells
exhibited greater migration and invasion than low-MMP cells.
This ﬁnding is consistent with previous reports that colon and
metastatic breast cancer cells with higher MMPs have greater
invasive potential.27,28
The drug-resistant cells that survive drug treatment enter
dormancy.29,30 As a result of persistent drug treatment, a
fraction of these cells produce colonies of cells with relatively
stable tolerance, and these exit dormancy.30 In this study, the
drug-resistant cell population was isolated by treatment with
cisplatin for 3 days and a further 2 days of culture in the
absence of cisplatin (Figure 3). The isolated cells continued to
survive but did not proliferate (Figures 3d and e), suggesting
that they were dormant. Because cisplatin affects
mitochondria,31 the MMP was measured 2 days after the
removal of cisplatin to exclude the possibility of drug-induced
changes in the MMP. The MMP of cisplatin-resistant dormant
cells was higher than that of the parental cells (Figure 3).
Because dormant, drug-resistant and stem-cell-like populations
of breast cancer cells are dependent on mitochondria for
energy production,13 the relationship between MMP and drug
resistance is likely not limited to NSCLC. Further investigation
of changes in MMP among parental cells, dormant drug-
resistant cells and drug-resistant cells that have exited from
dormancy will provide further information on the relationship
between MMP and drug resistance.
Mitochondria have been linked to metastasis32,33 due to their
production of reactive oxygen species, and the effect of
inhibition of mitochondrial complex 1 on metastasis is unclear.
Inhibition of mitochondrial complex 1 by gene knockdown has
been reported to promote migration.34 However, metformin,
a complex 1 inhibitor,35 was found to suppress metastasis of
breast cancer,36 ovarian cancer37 and melanoma.38 In this
study, Rotenone, a speciﬁc inhibitor of complex 1,25 inhibited
the migration/invasion of not only the overall population but
also the drug-resistant population of lung adenocarcinoma
cells. Treatment with nanomolar concentrations of Rotenone
inhibited migration/invasion without affecting cell viability
(Figure 4). Because 5 and 10 nM Rotenone inhibited complex 1
activity by ~ 11% and ~ 33%, respectively,39 and a micromolar
concentration of Rotenone is required to reduce the viability of
NSCLC cells,26 a slight reduction in mitochondrial complex 1
activity might affect metastasis but not cell viability. Although
many inhibitors of mitochondria are toxic, therapeutic
windows exist for their use against cancer.40–42 Thus, these
ﬁndings suggest that inhibitors of mitochondria can be used to
reduce the incidence of metastasis after platinum-based
therapy.
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